

# Orphan Drugs: Market Research Report

<https://marketpublishers.com/r/O139EB269E5EN.html>

Date: January 2019

Pages: 436

Price: US\$ 5,600.00 (Single User License)

ID: O139EB269E5EN

## Abstracts

This report analyzes the worldwide markets for Orphan Drugs in US\$ Million by the following Product Segments: Biologics, and Non-Biologics.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 140 companies including many key and niche players such as

-

AbbVie, Inc.

Actelion Pharmaceuticals Ltd.

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

AstraZeneca Plc

Bayer AG

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

A Prelude

**Table 1.** List of Orphan Drug Designation Criteria in Various Countries

**Table 2.** Select Orphan Diseases and their Prevalence (includes corresponding Graph/Chart)

Increasing Adoption of Orphan Drugs by Manufacturers

The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry

Major Orphan Drugs Legislations Worldwide

Orphan Drugs Market on a Rapid Growth Trajectory

**Table 3.** Orphan Drug Designations: 2010 to 2016 (includes corresponding Graph/Chart)

Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU

Incentives for Orphan Drug Designation Products in the US, EU, and Japan

Market Challenges

Obstacles for Conducting Orphan Drug Research

Competition

**Table 4.** Global Orphan Drugs Market by Leading Brand: Percentage Market Share for

2016 (includes corresponding Graph/Chart)

Orphan Drugs Remain Strong in the Pharmaceutical Pipeline  
Important Orphan Drugs in Pipeline

## **2. GROWTH DRIVERS**

Regulatory Incentives – A Push in the Right Direction  
Growing Unmet Medical Needs – Fulfilling the Gap  
Rising Incidence of Rare Forms of Cancer – Opportunities Galore

**Table 5.** Growing Burden of Cancer Worldwide - Number of New Cancer Cases and Cancer-Related Deaths for the Year 2012 and 2030 (includes corresponding Graph/Chart)

**Table 6.** Common Cause of Cancer Deaths Worldwide - Number of Deaths due to Select Types of Cancer for 2015 (includes corresponding Graph/Chart)

**Table 7.** New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart)

Select Orphan Drugs for Cancer  
Rise in Incidence of Renal Cell Carcinoma  
Unmet Needs in AML  
Aging Population Offers Growth Potential

**Table 8.** Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart)

Pre-Symptomatic Screening to Expand Market Base  
Asia's Rising Awareness and Growing Population to Drive Sales

## **3. SELECT MARKET TRENDS**

Drug Repurposing Provides Therapies for Rare Diseases

**Table 9.** Major Blockbuster Pharma Drugs Having Orphan Designation (includes corresponding Graph/Chart)

The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges  
Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics  
Mergers and Acquisitions Drive Market Growth  
Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016  
Growing Scrutiny over Skyrocketing Prices  
Orphan Drugs with High Prices: 2016

**Table 10.** Few Orphan Drug Novel Therapies with Exorbitant Prices (includes corresponding Graph/Chart)

Medical Advancements Foster Growth  
Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs

**Table 11.** Orphan Drug Prices (includes corresponding Graph/Chart)

**Table 12.** Orphan Drugs Vs Non-Orphan Drugs Average Cost (in Dollars) per Patient per Year 2012-2016 (includes corresponding Graph/Chart)

**Table 13.** Orphan Drugs Vs Non-Orphan Drugs Median Cost (in Dollars) per Patient per Year 2012-2016 (includes corresponding Graph/Chart)

Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs

**Table 14.** US FDA Approval of Ultra-Orphan Non-Cancer Drugs

Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis  
Increasing Patient Engagement – The PAG Trend  
Gene Therapy and Bioprocessing Preferred over Chronic Therapies  
Companies Developing Gene Therapies  
International Collaboration – The Way Forward  
CNS Therapeutics to Gain Focus in the Orphan Drugs Market

**Table 15.** CNS Orphan Drug Designations by Therapeutic Area: 2016 (includes corresponding Graph/Chart)

Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications  
Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications  
Treating Autism – The Next Big Thing?  
Sequencing Technology – The New Research Tool for Orphan Drugs  
Innovations in Biotechnology – A Boon for Orphan Drug Research  
Aging Gene Linked to Myeloma  
Antibody with Potential to Treat Multiple Myeloma  
Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus  
Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer

#### **4. ORPHAN DRUG FDA APPROVALS**

FDA Approved Orphan Drugs (as of July 2017)  
FDA Approved Orphan Drugs (2016)  
FDA Approved Orphan Drugs (2015)  
FDA-Approved Orphan Drugs (2015)

#### **5. ORPHAN DRUG DESIGNATIONS**

Select Orphan drug designation: 2017 (total 433 as of november 17, 2017)  
Select Orphan drug designations: 2016 (total 333)

#### **6. REGULATORY SCENARIO**

The Need for Regulation  
US – The Orphan Drug Act of 1983  
The Amended Pharmaceutical Law 1993 (Japan)  
The Australian Orphan Drugs Program – 1997  
The European Regulation on Orphan Medicinal Products – 1999

#### **7. PRODUCT OVERVIEW**

Orphan Drugs – A Prologue

**Table 16.** Number of Incidences Determining the Orphan Status of a Disease by Region

(includes corresponding Graph/Chart)

**Table 17.** Definitions of Orphan Diseases in Different Countries

Orphan Drugs Research Progress  
Select Orphan Disease Definitions  
Glioblastoma Multiforme  
Cystic Fibrosis  
Lysosomal Storage Disorders  
Fabry Disease  
Gaucher's Disease  
Pompe Disease  
Huntington's Disease  
Lymphoma  
Multiple Myeloma  
Atypical Hemolytic Uremic Syndrome (aHUS)  
Chronic Myelogenous Leukemia (CML)  
Cushing's syndrome  
Short Bowel Syndrome (SBS)  
Duchenne's Muscular Dystrophy (DMD)  
Hemophilia  
Homozygous Familial Hypercholesterolemia (hoFH)  
Idiopathic Pulmonary Fibrosis (IPF)  
Metastatic Melanoma  
Paroxysmal Nocturnal Hemoglobinuria (PNH)  
Ph+ALL  
Ultra-Orphan Drugs

**Table 18.** Select Ultra-Orphan Diseases with Global Registered Cases but No Available Prevalence Data (includes corresponding Graph/Chart)

Orphan Drug Categorization  
Designation of Orphan Status  
Personalized Medicine and Orphan Drugs  
Regulatory Differences between the US and EU

## **8. SELECT PRODUCT APPROVALS/LAUNCHES**

TiGenix Receives FDA Orphan Drug Designation for Cx601  
FDA Grants Orphan Drug Designation for Emerald Health Pharmaceuticals lead molecule, EHP-101, to Treat Systemic Scleroderma  
RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON  
FDA Awards Orphan Drug Status to uniQure's Potential Huntington's Therapy  
Boston Biomedical Receives Orphan Drug Designation from FDA for DSP-7888  
Amicus Receives FDA Orphan Drug Status for ATB200/AT2221  
Roche's Actemra/RoActemra (tocilizumab) Receives FDA Approval to Treat CAR T Cell-induced Cytokine Release Syndrome  
AGTC Receives FDA Orphan Drug Designation for Gene Therapy Product Candidate Polyneuron' PN-1007 Receives Orphan Drug Status from European Medicines Agency  
FDA Grants Orphan Drug Designation to Versantis VS-01  
Innovate Biopharmaceuticals Applies for FDA's Orphan Drug Designation for INN-108  
FDA Grants Orphan Drug Status for Biohaven's BHV-5000  
Mithra Receives Orphan Drug Designation for E4  
AstraZeneca Receives Orphan Designation from EMA for inebilizumab  
Boehringer Ingelheim gets FDA Orphan Drug Status for BI 836858  
Biostage gets FDA Orphan Drug Designation for Cellspan Esophageal Implant  
AbbVie Obtains FDA Orphan Drug Designation for Risankizumab  
AbbVie gets FDA Orphan Drug Designation for Veliparib  
TiGenix Receives Orphan Drug Designation for Cx601  
Boehringer Ingelheim gets FDA Orphan Drug Designation for nintedanib  
AstraZeneca Receives FDA Orphan Drug Designation for Selumetinib  
Amarantus gets FDA Orphan Drug Designation for Eltoprazine  
AM-Pharma Secures FDA & EMA Orphan Drug Designation  
AstraZeneca's Tremelimumab Receives FDA Orphan Drug Designation  
BioArbitrage chooses to focus on the Dynamic Rare Disease Sector  
Acer Therapeutics ACER-002 Receives FDA Orphan Drug Designation

## **9. RECENT INDUSTRY ACTIVITY**

Ergomed Plc Plans to Acquire PSR Group BV  
UDG Healthcare Acquires Cambridge BioMarketing  
Horizon Pharma Acquires River Vision Development Corp. and Teprotumumab  
Sun Pharma's Indirect arm Taro Announces Acquisition of Thallion Pharmaceuticals  
Johnson & Johnson Plans to Acquire Actelion  
Escend Offers Opportunity to Acquire or License ES-3000  
Horizon Pharma Agrees to Take Over Raptor Pharmaceutical  
Savara Acquires Serendex Pharmaceuticals

InSite Vision Inks definitive Agreement with QLT Inc  
Roche Plans to Take over Trophos

## 10. FOCUS ON SELECT PLAYERS

AbbVie, Inc. (USA)  
Actelion Pharmaceuticals Ltd. (Switzerland)  
Alexion Pharmaceuticals, Inc. (USA)  
Amgen, Inc. (USA)  
AstraZeneca Plc. (UK)  
Bayer AG (Germany)  
Biogen Inc. (USA)  
BioMarin Pharmaceutical Inc. (USA)  
Boehringer Ingelheim GmbH (Germany)  
Bristol-Myers Squibb Company (USA)  
Celgene Corp. (USA)  
CEL-SCI Corporation (USA)  
Concordia International Corp. (Canada)  
Eli Lilly and Company (USA)  
F. Hoffmann-La Roche Ltd. (Switzerland)  
Johnson & Johnson (USA)  
Merck & Co., Inc. (USA)  
Merck Serono International S. A. (Germany)  
Novartis AG (Switzerland)  
Pfizer, Inc. (USA)  
Recordati S. p. A. (Italy)  
Orphan Europe (France)  
Shire Plc. (Ireland)  
Sanofi SA (France)  
Genzyme Corp. (USA)  
Vertex Pharmaceuticals (USA)

## 11. GLOBAL MARKET PERSPECTIVE

**Table 19.** World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)



**Table 20.** World Historic Review for Orphan Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 21.** World 14-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Analysis by Product Segment

**Table 22.** World Recent Past, Current & Future Analysis for Orphan Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 23.** World Historic Review for Orphan Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed With Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 24.** World 14-Year Perspective for Orphan Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 25.** World Recent Past, Current & Future Analysis for Orphan Non-Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 26.** World Historic Review for Orphan Non-Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 27.** World 14-Year Perspective for Orphan Non-Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

A. Market Analysis  
Current and Future Analysis

**Table 28.** Prevalence and Prices of Select Orphan Drugs in the US (includes corresponding Graph/Chart)

**Table 29.** Leading Drugs in the US Orphan Drugs Market: Market Share of Sales in Percentage for the year 2016 (includes corresponding Graph/Chart)

Orphan Drug Act – A Milestone Legislation  
US Leads the Orphan Drug Approval Landscape

**Table 30.** Number of Orphan Drug Approvals and Designations: 1983 to 2016 (includes corresponding Graph/Chart)

**Table 31.** Number of FDA Approved Orphan Drugs by Type: 2013-2016 (includes corresponding Graph/Chart)

Regulatory Overview  
US Orphan Drugs Policy - A Snapshot  
Orphan Products Grants Program  
Humanitarian Use Device (HUD) Program  
Select CDRH Approved Devices for Rare Diseases  
Medicare Reimbursement for Orphan Drugs  
Reimbursement for Orphan Drugs Not on Single-Indication List  
Orphan Drug Modernization Plan  
Priority Review of Orphan Drugs Becomes Popular  
FDA Review Time Reduced for Priority Review Designation

**Table 32.** Majority of Orphan Drugs Undergo Priority Review: 2015 (includes corresponding Graph/Chart)

Product Approvals  
Strategic Corporate Developments  
Select Key Players  
B. Market Analytics

**Table 33.** The US Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 34.** The US Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 35.** The US 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 2. JAPAN

A. Market Analysis  
Current and Future Analysis  
Regulatory Overview

**Table 36.** Comparison of Japanese Orphan Drug Designation System with the US and Europe

New Orphan Drugs in Japan: 2015-2017

**Table 37.** Japanese Orphan Drugs Designation by Therapeutic Area: 2016 (includes corresponding Graph/Chart)

B. Market Analytics

**Table 38.** Japanese Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 39.** Japanese Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 40.** Japanese 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

### 3. EUROPE

A. Market Analysis  
Current and Future Analysis

**Table 41.** Leading Drugs in the European Orphan Drugs Market: Market Share of Sales in Percentage for the year 2016 (includes corresponding Graph/Chart)

**Table 42.** European Orphan Medicinal Product Designations since 2008 (includes corresponding Graph/Chart)

**Table 43.** EU Orphan Designation by Therapeutic Indications: As of 2015 (includes corresponding Graph/Chart)

Orphan Drug Marketing Authorizations in Europe: As of Sept 2017

Orphan Drug Marketing Authorizations in Europe: 2016

The European Regulation on Orphan Medicinal Products - 1999

EU Orphan Drug Regulation Overview

Orphan Drugs Policies Summary in Select European Countries

Product Approvals

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 44.** European Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 45.** European Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 46.** European 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## **4. REST OF WORLD**

### **A. Market Analysis**

#### **Current and Future Analysis**

Asia's Rising Awareness and Growing Population to Drive Sales

Orphan Drugs Legislation in Select Asia-Pacific Countries: 2014

Regulatory Scenario in Select Countries

Australia

China

Orphan Drugs Market Set to Grow in China

The Chinese Food and Drug Administration (CFDA)

India

Lack of Awareness Limits the Growth of Orphan Drug Development

Malaysia

Malaysia to Develop a National Framework for the Management of Rare Diseases

Thailand

Singapore

South Africa

South Korea

Taiwan

Strategic Corporate Development

Select Key Player

### **B. Market Analytics**

**Table 47.** Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 48.** Rest of World Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 49.** Rest of World 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 140 (including Divisions/Subsidiaries - 151)

The United States (77)

Canada (8)

Japan (8)

Europe (51)

France (10)

Germany (4)

The United Kingdom (7)

Italy (3)

Rest of Europe (27)

Asia-Pacific (Excluding Japan) (3)

Middle East (4)

## I would like to order

Product name: Orphan Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/O139EB269E5EN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O139EB269E5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970